“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A trial looking at blinatumomab for acute lymphoblastic leukaemia (ALL)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial used blinatumomab to reduce the small number of leukaemia cells left in the blood after treatment for B cell acute lymphoblastic leukaemia.
This trial was open for people to join between 2010 and 2013. The researchers published the results in 2018.
More about this trial
When you finish chemotherapy, you have tests to see how it has worked. But sometimes there are a small number of leukaemia cells still in the blood. This is minimal residual disease (MRD). The leukaemia will come back (recur) if these cells start to grow again. Doctors hoped that blinatumomab would prevent or delay this happening.
Blinatumomab is a type of targeted drug called a monoclonal antibody. Monoclonal antibodies seek out cancer cells by looking for certain proteins on the cells’ surface.
The aim of this trial was to find out how well blinatumomab worked for people who had MRD.
Summary of results
- 88 people had no leukaemia cells - they were MRD negative after 1 cycle
- 2 people had no leukaemia cells - they were MRD negative after 2 cycles
- 23 people had leukaemia cells after treatment - they were still MRD positive
- high temperature (fever)
- a drop in blood cells causing an increased risk of infection, bleeding problems, tiredness and breathlessness
- problems with the
central nervous systemsuch as tremors, dizziness or confusion
- liver changes
How to join a clinical trial
Professor Adele Fielding
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer